Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
Therapeutic product discovery
In the information age
The next wave in immuno-oncology
Feb 15, 2017
Compugen Reports Fourth Quarter and Calendar Year 2016 Results
Jan 30, 2017
Compugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST
Our optimized process for predictive discovery of novel drug targets
Discovery & development of first-in-class monoclonal antibody therapeutics
CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen
CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad industry interest in the field...
CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15022 is expressed in numerous types of epithelial cancers, such...
CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
CGEN-15029 is also being assessed for anti-cancer activity through a different mechanism of action, by engaging effector cells of the immune system to directly...
Feb 22, 2017
Compugen to Present at Molecular Med Tri-Conference 2017
San Francisco, CA
In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Click here for more info about partnering with Compugen